Corona Remedies Ltd (CORONA) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

24.85 k (-66.40%) Volume

Shareholding (Jun 2026)

FII

3.63%

Held by 37 FIIs

DII

12.90%

Held by 16 DIIs

Promoter

69.00%

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Flat results in Mar 26

PBT LESS OI(Q) At Rs 50.63 cr has Fallen at -15.8% (vs previous 4Q average)

With ROE of 26.8, it has a Very Expensive valuation with a 13.9 Price to Book Value

Increasing Participation by Institutional Investors

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

INR 12,652 Cr ()

P/E

60.00

Industry P/E

Dividend Yield

0.49%

Debt Equity

0.00

Return on Equity

0.00%

Price to Book

16.90

Revenue and Profits:

Net Sales:

422 Cr

(Quarterly Results - Jun 2026)

Net Profit:

60 Cr

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0.49%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

21.48%

6 Months

27.43%

1 Year

0.0%

2 Years

0.0%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Corona Remedies for the last several years.

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

Corona Remedies Ltd Downgraded to Sell Amid Technical and Financial Concerns

Corona Remedies Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 19 May 2026. This shift reflects a combination of deteriorating technical indicators, flat recent financial performance, and valuation concerns despite the company’s strong return on capital employed and institutional investor interest.

Has Corona Remedies Ltd declared dividend?

Corona Remedies Ltd has declared a 100% dividend. Dividend Details: - Percentage announced: 100% - Ex-date: 19 Jun 26 Dividend Yield: 0% Total Returns by Period: In the last 3 months, the price return was 7.52%, the dividend return was 0%, resulting in a total return of 7.52%. Over the last 6 months, there was no price return or dividend return, leading to a total return of 0.0%. For the 1-year period, there was no price return or dividend return, resulting in a total return of 0.0%. In the last 2 years, there was no price return or dividend return, leading to a total return of 0.0%. For the 3-year period, there was no price return or dividend return, resulting in a total return of 0.0%. In the last 4 years, there was no price return or dividend return, leading to a total return of 0.0%. Over the last 5 years, there was no price return or dividend return, resulting in a total return of 0.0%. Overa...

Corona Remedies Ltd Quality Grade Upgrade Reflects Strengthened Business Fundamentals

Corona Remedies Ltd has recently seen its quality grade upgraded from "does not qualify" to "good," reflecting notable improvements in its core business fundamentals. This upgrade, announced on 12 May 2026, highlights enhanced operational efficiency, robust capital returns, and prudent debt management, positioning the small-cap pharmaceutical company favourably within its sector despite recent share price volatility.

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

03-Aug-2026 | Source : BSE

Audio Recording of Q1 FY27 Earnings Conference Call with Analysts / Investors

Announcement under Regulation 30 (LODR)-Newspaper Publication

01-Aug-2026 | Source : BSE

Newspaper Publication of Unaudited Financial Results for the first quarter and three months ended June 30 2026

Board Meeting Outcome for Outcome Of Board Meeting

31-Jul-2026 | Source : BSE

Outcome of Board Meeting

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

Corona Remedies Ltd has declared 100% dividend, ex-date: 19 Jun 26

SPLITS

No Splits history available

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

EBIT to Interest (avg)

27.90

Debt to EBITDA (avg)

0.56

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

1.54

Tax Ratio

23.03%

Dividend Payout Ratio

30.00%

Pledged Shares

Institutional Holding

16.53%

ROCE (avg)

29.49%

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

17.05

EV to EBIT

50.25

EV to EBITDA

43.76

EV to Capital Employed

14.82

EV to Sales

9.15

PEG Ratio

Dividend Yield

0.48%

ROCE (Latest)

29.49%

ROE (Latest)

26.75%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

KST

Dow Theory

Bullish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jun 2026

Shareholding Compare (%holding)

Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 13 Schemes (12.5%)

FIIs

Held by 37 FIIs (3.63%)

Promoter with highest holding

Ankurbhai K Mehta (22.0%)

Highest Public shareholder

Sepia Investments Limited (12.68%)

Individual Investors Holdings

0.89%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Jun'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is 19.64% vs 3.12% in Mar 2026",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is 33.41% vs 9.21% in Mar 2026",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'26",
        "Mar'26",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "422.43",
          "val2": "353.09",
          "chgp": "19.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "93.13",
          "val2": "62.02",
          "chgp": "50.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.69",
          "val2": "1.38",
          "chgp": "94.93%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "60.10",
          "val2": "45.05",
          "chgp": "33.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "22.05%",
          "val2": "17.56%",
          "chgp": "4.49%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "alert": "No Half Yearly Results declared by Corona Remedies"
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "alert": "No Nine Monthly Results declared by Corona Remedies"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,403.18",
          "val2": "1,196.42",
          "chgp": "17.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "293.44",
          "val2": "239.98",
          "chgp": "22.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "6.97",
          "val2": "10.60",
          "chgp": "-34.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-19.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "184.85",
          "val2": "149.05",
          "chgp": "24.02%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "20.91%",
          "val2": "20.06%",
          "chgp": "0.85%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Jun'26 - QoQ

Jun'26

Mar'26

Change(%)

Net Sales

422.43

353.09

19.64%

Operating Profit (PBDIT) excl Other Income

93.13

62.02

50.16%

Interest

2.69

1.38

94.93%

Exceptional Items

0.00

Standalone Net Profit

60.10

45.05

33.41%

Operating Profit Margin (Excl OI)

22.05%

17.56%

4.49%

Values in Rs Cr.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2026 is 19.64% vs 3.12% in Mar 2026

Standalone Net Profit

QoQ Growth in quarter ended Jun 2026 is 33.41% vs 9.21% in Mar 2026

All Quarterly Results

Annual Results Snapshot (Standalone) - Mar'26

Mar'26

Mar'25

Change(%)

Net Sales

1,403.18

1,196.42

17.28%

Operating Profit (PBDIT) excl Other Income

293.44

239.98

22.28%

Interest

6.97

10.60

-34.25%

Exceptional Items

-19.10

0.00

Standalone Net Profit

184.85

149.05

24.02%

Operating Profit Margin (Excl OI)

20.91%

20.06%

0.85%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Annual Results

Company CV

About

Company Coordinates

Company Details

Tel:

Registrar Details

Name: MOJO Markets Private Limited (Research Entity) (SEBI Registration No. INH000021942) (CIN:U74900MH2015PTC264951)

Registered & Correspondence Address: Benefice Business House, Office No. 3B, 3rd Floor, C.S. 242, Mathuradas Mills Estate, N.M. Joshi Marg, Tulsi Pipe Road, Lower Parel West, Mumbai- 400013

For queries or grievances, please contact us on support.ra@mojomarkets.in, Phone : 022-35121239

"Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors."

Corona Remedies

1Day

52 Week

CASH

FII

DII

Promoter

Dashboard

Flat results in Mar 26

With ROE of 26.8, it has a Very Expensive valuation with a 13.9 Price to Book Value

Increasing Participation by Institutional Investors

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

Returns Beta

News

Corona Remedies Ltd Downgraded to Sell Amid Technical and Financial Concerns

Has Corona Remedies Ltd declared dividend?

Corona Remedies Ltd Quality Grade Upgrade Reflects Strengthened Business Fundamentals

Announcements

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Announcement under Regulation 30 (LODR)-Newspaper Publication

Board Meeting Outcome for Outcome Of Board Meeting

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Jun 2026

Shareholding Compare (%holding)

Quarterly Results Snapshot (Standalone) - Jun'26 - QoQ

Annual Results Snapshot (Standalone) - Mar'26

About

Company Coordinates